News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,005 Results
Type
Article (14645)
Company Profile (285)
Press Release (252075)
Section
Business (80235)
Career Advice (155)
Deals (13327)
Drug Delivery (34)
Drug Development (51608)
Employer Resources (31)
FDA (5816)
Job Trends (5271)
News (146306)
Policy (10206)
Tag
Academia (941)
Alliances (21865)
Alzheimer's disease (787)
Antibody-drug conjugate (ADC) (72)
Approvals (5799)
Artificial intelligence (92)
Bankruptcy (100)
Best Places to Work (4697)
Biotechnology (233)
Breast cancer (123)
Cancer (1105)
Cardiovascular disease (84)
Career advice (135)
CAR-T (86)
Cell therapy (252)
Clinical research (41414)
Collaboration (407)
Compensation (156)
COVID-19 (1027)
C-suite (104)
Cystic fibrosis (72)
Data (1092)
Diabetes (98)
Diagnostics (1288)
Earnings (29448)
Events (48135)
Executive appointments (326)
FDA (6269)
Funding (381)
Gene editing (72)
Gene therapy (187)
GLP-1 (342)
Government (1117)
Healthcare (6690)
Infectious disease (1068)
Inflammatory bowel disease (101)
IPO (7291)
Job creations (871)
Job search strategy (129)
Layoffs (205)
Legal (1389)
Lung cancer (166)
Lymphoma (68)
Manufacturing (95)
Medical device (2576)
Medtech (2577)
Mergers & acquisitions (6244)
Metabolic disorders (298)
Neuroscience (1082)
NextGen: Class of 2025 (2045)
Non-profit (870)
Northern California (1257)
Obesity (162)
Opinion (93)
Parkinson's disease (86)
Patents (72)
People (25408)
Phase I (14636)
Phase II (19238)
Phase III (12234)
Pipeline (473)
Postmarket research (858)
Preclinical (6108)
Radiopharmaceuticals (209)
Rare diseases (231)
Real estate (1419)
Regulatory (8532)
Research institute (981)
Series A (77)
Southern California (1125)
Startups (1978)
United States (9972)
Vaccines (189)
Weight loss (94)
Date
Last 7 days (383)
Last 30 days (1574)
Last 365 days (20656)
2025 (1625)
2024 (20832)
2023 (22765)
2022 (27254)
2021 (28265)
2020 (23779)
2019 (16606)
2018 (11990)
2017 (14080)
2016 (12096)
2015 (14564)
2014 (10481)
2013 (7508)
2012 (7561)
2011 (7621)
2010 (7431)
Location
Africa (147)
Asia (17370)
Australia (2940)
California (2867)
Canada (900)
China (258)
Colorado (106)
Connecticut (118)
Europe (37379)
Florida (325)
Georgia (84)
Illinois (183)
Indiana (70)
Maryland (380)
Massachusetts (2270)
Minnesota (113)
New Jersey (731)
New York (788)
North Carolina (453)
Northern California (1257)
Ohio (91)
Pennsylvania (537)
South America (208)
Southern California (1125)
Texas (323)
Washington State (278)
267,005 Results for "checkpoint therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
December 16, 2024
·
15 min read
Genetown
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
Checkpoint Therapeutics, Inc. today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab.
June 24, 2024
·
5 min read
Business
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates.
May 10, 2024
·
9 min read
Press Releases
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 12, 2024
·
10 min read
Business
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.
March 22, 2024
·
10 min read
Genetown
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET.
May 13, 2024
·
1 min read
Stomach cancer
FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1
The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.
August 23, 2024
·
2 min read
·
Tristan Manalac
Genetown
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target
GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
April 24, 2024
·
2 min read
Press Releases
Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
November 20, 2024
·
3 min read
Press Releases
Virion Therapeutics Reports First-Ever Clinical Responses with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at AASLD’s The Liver Meeting®
November 19, 2024
·
6 min read
1 of 26,701
Next
